KR100913258B1 - 질환-관련 단백질 - Google Patents

질환-관련 단백질 Download PDF

Info

Publication number
KR100913258B1
KR100913258B1 KR1020037012934A KR20037012934A KR100913258B1 KR 100913258 B1 KR100913258 B1 KR 100913258B1 KR 1020037012934 A KR1020037012934 A KR 1020037012934A KR 20037012934 A KR20037012934 A KR 20037012934A KR 100913258 B1 KR100913258 B1 KR 100913258B1
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
leu
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037012934A
Other languages
English (en)
Korean (ko)
Other versions
KR20030094317A (ko
Inventor
티에리 레베이야르
조제 알렝 샤엘
사덱 모앙-세
데이비드 힉스
Original Assignee
노파르티스 아게
유니베르시떼 루이 파스퇴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 유니베르시떼 루이 파스퇴르 filed Critical 노파르티스 아게
Publication of KR20030094317A publication Critical patent/KR20030094317A/ko
Application granted granted Critical
Publication of KR100913258B1 publication Critical patent/KR100913258B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020037012934A 2001-04-06 2002-04-05 질환-관련 단백질 Expired - Lifetime KR100913258B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
FR01/04712 2001-04-06
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Publications (2)

Publication Number Publication Date
KR20030094317A KR20030094317A (ko) 2003-12-11
KR100913258B1 true KR100913258B1 (ko) 2009-08-21

Family

ID=8862037

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037012934A Expired - Lifetime KR100913258B1 (ko) 2001-04-06 2002-04-05 질환-관련 단백질

Country Status (22)

Country Link
US (6) US7795387B2 (enExample)
EP (1) EP1379657B1 (enExample)
JP (2) JP4370428B2 (enExample)
KR (1) KR100913258B1 (enExample)
CN (1) CN1529753B (enExample)
AU (1) AU2002312794B8 (enExample)
BR (1) BRPI0208870B8 (enExample)
CA (1) CA2443345C (enExample)
CZ (1) CZ305800B6 (enExample)
EC (1) ECSP024345A (enExample)
ES (1) ES2597835T3 (enExample)
FR (1) FR2823221B1 (enExample)
HU (1) HU226307B1 (enExample)
IL (3) IL158013A0 (enExample)
MX (1) MXPA03009114A (enExample)
NO (1) NO331277B1 (enExample)
NZ (1) NZ528376A (enExample)
PL (1) PL213658B1 (enExample)
RU (1) RU2384586C2 (enExample)
SK (1) SK288465B6 (enExample)
WO (1) WO2002081513A2 (enExample)
ZA (1) ZA200307403B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
EP2281047B1 (en) * 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
WO2010029130A1 (en) * 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
WO2013063383A2 (en) * 2011-10-27 2013-05-02 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
WO2014060517A1 (en) * 2012-10-17 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd)
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
WO2016185242A1 (en) 2015-05-21 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of neuronal viability factors and uses thereof
WO2017120294A1 (en) 2016-01-05 2017-07-13 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US10946063B2 (en) * 2016-10-11 2021-03-16 Welltat Ophthalmics Corporation Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
US20230146121A1 (en) * 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院(北京大学第三临床医学院) 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2010029130A1 (en) 2008-09-10 2010-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal viability factor and use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EBI Acceession No.BC02191*
EBI Acceession No.Q8VC33*
EBI accession No.AK015847
EBI accession No.BC014127
EBI accession No.BC016199
EBI accession No.BC022521
EBI accession No.BG294111

Also Published As

Publication number Publication date
CA2443345A1 (en) 2002-10-17
US8394756B2 (en) 2013-03-12
JP4571695B2 (ja) 2010-10-27
BRPI0208870B8 (pt) 2021-05-25
IL158013A0 (en) 2004-03-28
JP2009232843A (ja) 2009-10-15
CZ305800B6 (cs) 2016-03-23
WO2002081513A3 (en) 2003-05-01
MXPA03009114A (es) 2004-11-22
CA2443345C (en) 2012-12-04
SK12232003A3 (sk) 2004-03-02
ZA200307403B (en) 2004-04-21
US20040204350A1 (en) 2004-10-14
US20080004231A1 (en) 2008-01-03
US8114849B2 (en) 2012-02-14
FR2823221A1 (fr) 2002-10-11
PL213658B1 (pl) 2013-04-30
US20120108657A1 (en) 2012-05-03
US8957043B2 (en) 2015-02-17
JP2005502319A (ja) 2005-01-27
BR0208870A (pt) 2004-04-27
EP1379657A2 (en) 2004-01-14
US8518695B2 (en) 2013-08-27
NO20034452L (no) 2003-12-04
ES2597835T3 (es) 2017-01-23
RU2003130638A (ru) 2005-04-20
US7795387B2 (en) 2010-09-14
JP4370428B2 (ja) 2009-11-25
US20120108523A1 (en) 2012-05-03
KR20030094317A (ko) 2003-12-11
ECSP024345A (es) 2004-06-28
AU2002312794B8 (en) 2006-01-12
CN1529753A (zh) 2004-09-15
SK288465B6 (sk) 2017-06-02
HU226307B1 (en) 2008-08-28
HUP0303730A2 (en) 2006-02-28
IL158013A (en) 2010-12-30
CN1529753B (zh) 2013-06-12
EP1379657B1 (en) 2016-08-17
FR2823221B1 (fr) 2004-04-02
CZ20032706A3 (cs) 2003-12-17
WO2002081513A2 (en) 2002-10-17
NO331277B1 (no) 2011-11-14
BRPI0208870B1 (pt) 2016-01-12
NZ528376A (en) 2005-09-30
IL199316A (en) 2011-01-31
NO20034452D0 (no) 2003-10-03
US20090062188A1 (en) 2009-03-05
AU2002312794B2 (en) 2005-12-01
PL364681A1 (en) 2004-12-13
US20130287738A1 (en) 2013-10-31
RU2384586C2 (ru) 2010-03-20
US8071745B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
US8071745B2 (en) Polynucleotides encoding rod-derived cone viability factor (rdcvf) and methods of using the same
US9353162B2 (en) Disease-associated proteins
AU2002312794A1 (en) Disease-associated protein
JP2008154583A (ja) インターロイキン−1関連遺伝子およびタンパク質
US20080075713A1 (en) Protein Disulfide Isomerase and ABC Transporter Homologous Proteins Involved in the Regulation of Energy Homeostasis
HK1061692B (en) Disease-associated protein
EP1373500A2 (en) Gene involved in v(d)j recombination and/or dna repair

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031002

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070405

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080528

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20081211

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080528

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090313

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20081211

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090513

Appeal identifier: 2009101002299

Request date: 20090313

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090413

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090313

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080728

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20090513

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20090420

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090813

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130723

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140722

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140722

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150716

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150716

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160720

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170804

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180730

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180730

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190729

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190729

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20200730

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20210728

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20221005

Termination category: Expiration of duration